Stem Cell Therapy
According to current research on stem cell transplantation in the world, it can be used to treat more than 70 diseases, including spinal cord injury sequelae, cerebral palsy, cerebral hemorrhage, Parkinson, stroke, senile dementia, diabetes mellitus, heart disease, liver disease, autism, joint injury, arthralgia, etc.
At present, in the field of stem cell therapy, the United States has many outstanding scientists in fundamental research. They put forward many good ideas and this is closely related to the advanced education in the United States.
China is in the forefront on stem cell clinical application in the world. The large population base and relatively loose policy environment enables Chinese doctors to have more clinical experience, which is China’s unparalleled advantage. ICT U.S. Chief Medical Officer of China Clinical Application Center, Director of the Cell Transplantation Department of The Third Medical Center of Chinese PLA General Hospital is the pioneer. As early as 2004, the world’s first stem cell transplantation specialist was established. In 2006, it was approved by the Chinese military and allowed to do clinical trials. In the past 14 years, more than 10,000 patients have been treated, with more than 85% effective rate.
ICT U.S. has been focusing on fundamental research and clinical application for stem cell transplantation for many years. We have rich clinical experience for different diseases. A total of 26 clinical trials at NIH (National Institutes of Health) and WHO (World Health Organization) are registered. In particular, stem cell transplantation for the treatment of bone marrow injury sequelae and stem cell transplantation for the treatment of cerebral palsy, all of which have been approved by the FDA-authorized NIH through Phase III clinical trials. It became the first institution in the world to have two phases passed through three phases of clinical practice.
ICT U.S. Medical Solutions
IVY-01 Umbilical cord-derived mesenchymal stem cell inhibits pain solution (Can be used in both North America and China)
ICT U.S. Medical Solutions in China(only)
IVY-02 Umbilical cord-derived mesenchymal stem cells for treatment of Parkinson
IVY-03 Umbilical cord-derived mesenchymal stem cells for the treatment of cerebral palsy
IVY-04 Umbilical cord-derived mesenchymal stem cells to delay motor neuron disease
IVY-05 Umbilical cord-derived mesenchymal stem cells to treat joint injury and cartilage repair
IVY-06 Umbilical cord-derived mesenchymal stem cells to delay cirrhosis
IVY-07 Umbilical cord-derived mesenchymal stem cells for the treatment of lower limb artery occlusion
Patients can take out and manufacture MSCs and other biological samples from their own or allogeneic umbilical cord tissue stored in the ICT U.S. Biobank. Stem cell therapy for related diseases can also be carried out in our partnership institutions through allogeneic MSCs provided by ICT U.S., and we are responsible for the delivery of all biological products during the period of therapy.